Format

Send to

Choose Destination
Lung Cancer. 2019 Oct;136:74-79. doi: 10.1016/j.lungcan.2019.08.011. Epub 2019 Aug 14.

An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer.

Author information

1
Washington University School of Medicine, St. Louis, MO, USA.
2
St. Petersburg City Oncology Dispensary, St. Petersburg, Russian Federation.
3
Servicio de Oncologia, Hospital General Universitario Vall d'Hebron, Barcelona, Spain.
4
Hospital Infanta Cristina, Badajoz, Spain.
5
Arkhangelsk Regional Oncology Dispensary, Arkhangelsk, Russian Federation.
6
Fundación Jiménez Díaz, Madrid, Spain.
7
University of California, Davis Medical Center, Sacramento, CA, USA.
8
Memorial Sloan Kettering Cancer Center, New York, NY, USA.
9
Department of Oncology Rigshospitalet, Copenhagen, Denmark.
10
First Pavlov State Medical University, St. Petersburg, Russian Federation.
11
Hospital Universitario Virgen de la Victoria, Málaga, Spain.
12
Regional Clinical Oncology Dispensary, Ryazan, Russian Federation.
13
GlaxoSmithKline, Inc., Collegeville, PA, USA.
14
GlaxoSmithKline, Inc., Collegeville, PA, USA. Electronic address: maurice.p.deyoung@gsk.com.
15
Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain. Electronic address: pilargarridol@gmail.com.

Abstract

OBJECTIVES:

GSK3052230 (FP-1039) is a soluble fusion protein that acts as ligand trap sequestering fibroblast growth factors (FGFs) involved in tumor growth and angiogenesis, while sparing the hormonal FGFs. Because of this selectivity, the molecule is predicted to avoid toxicities associated with small molecule inhibitors of FGFR, including hyperphosphatemia and retinal, nail, and skin toxicities. Herein we report the results of a phase 1b study where GSK3052330 was administered with standard of care chemotherapy in FGFR1-amplified squamous non-small cell lung cancer (sqNSCLC) patients.

METHODS AND METHODS:

Eligible patients with stage IV or recurrent metastatic sqNSCLC harboring FGFR1 gene amplification received escalating doses of GSK3052230 in combination with paclitaxel and carboplatin at the starting doses 200 mg/m2 and AUC of 6, respectively, in the first line setting (Arm A) or docetaxel 75 mg/m2 in second line (Arm B). The primary endpoints of the study were safety and tolerability, to identify a maximum tolerated dose (MTD), and to assess overall response rate (ORR) based on investigator assessment.

RESULTS:

Twenty-nine patients were enrolled into the study, including 20 patients on Arm A and 9 patients on Arm B. There were no dose limiting toxicities in either Arm and the MTD was not reached. The most common adverse events (AEs) were compatible with the chemotherapy backbone used in each Arm, including neutropenia, alopecia, nausea, arthralgia, asthenia, diarrhea and peripheral neuropathy. The overall response rate and median progression-free survival were 47% and 5.5 months, respectively, for Arm A and 0% and 4.6 months, respectively, for Arm B.

CONCLUSION:

GSK3052230 is a novel FGFR pathway inhibitor, which is well tolerated in combination with chemotherapy. Importantly, AEs associated with small molecule inhibitors of FGFR were not observed, as predicted by the unique mechanism of action of this drug.

KEYWORDS:

Combination therapy; FGFR1; Ligand trap; Phase 1; Squamous non-small cell lung cancer

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center